1 / 16

Australian Imaging Biomarkers Study: Update & Future Directions

Explore the AIBL study on ageing, cognitive decline, and AD with neuroimaging data. Discover insights on genetic factors, lifestyle influences, and future clinical trials.

irenek
Download Presentation

Australian Imaging Biomarkers Study: Update & Future Directions

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. . The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing (AUSTRALIAN ADNI) July 2015 UPDATE Christopher Rowe MD – Neuroimaging stream leader

  2. AIBL commenced recruitment in October 2006. Total Recruitment to Date = 1550. 397 NMC 619 SMC 234 MCI 291 AD 5 Non-AD 0m 361 NMC 499 SMC 139 MCI 246 AD 5 Non-AD 18m 311 NMC 348 SMC 66 MCI 170 AD Enrichment follow-up 6 Non-AD 36m 261 NMC 299SMC 51 MCI 102 AD 5 Non-AD 54m 213 NMC 271 SMC 48 MCI 59 AD 7 Non-AD Inception follow-up 72m 105 NMC 141 SMC 17 MCI 12 AD 4 Non-AD 90m Person years

  3. AD Mean Detectable yrs AIBL Highlights Ab PET has defined the course of AD Villemagne VL, et al.Lancet Neurology 2013 - diagnostic, prognostic and therapeutic implications Continually under refinement. Aβ+ ε4- Genes and lifestyle influences on decline Lim YY et al. Molecular Psychiatry 2014 Aβ+ ε4+ BDNFVal/Val Aβ+ ε4+ BDNFMet GWAS and SNP analyses underway. 0 10 20 30

  4. 4.5 year imaging data release PiB Baseline (288), 3 years (173), 4.5 yrs (141) Plus 230 more imaged with flutemetamol,florbetapir or PiB at 3 or 4.5 yrs Plus 245 new recruits (150 flute, 95 FBP) (Ab status known in 371 subjects with 4.5 yrs of follow-up) www.adni.loni.usc.edu - Data and Samples - Access Data

  5. Implemented the Centiloid transformation for 11C-PiB and 18F-NAV4694 with 18F-Florbetapir to follow. GAAIN Centiloid GAAIN PiB SUVR

  6. Tau Imaging AV1451 THK5117 (now replaced with THK5351) Beta-amyloid Tau

  7. THK5317 tau imaging in Alzheimer’s disease Ab tau Braak & Braak Stage V-VI Braak & Braak Stage C 18F-THK5317 18F-FLUTEMETAMOL MilxView

  8. 18F-THK5351 PET Normal 71 yr old. MMSE 29. Mild tau tracer retention in anteromedial temporal lobe but much less than in AD Negative Ab PET

  9. Ab PET +ve 69 yrs old female with MCI MMSE 24 CDR 0.5 Tau PET – right top and bottom - 18F-THK5351

  10. 64 yrs with “AD” but Ab PET Negative Memory -3 SD Other domains OK MMSE 28 CDR 1 THK5351 shows high medial temporal tau

  11. Screening for AD Drug Trials • FDG and amyloid PET if: • MCI/mild AD (CVLT <-1 SD) • trial suitable • willing to go into a drug trial • Reports go to treating doctor. • That doctor chooses trial or asks us to do this. • All scanned patients enrol in AIBL • - more MCI/AD baseline data • - good source of Ab –ve MCI and AD mimics - (20%) To date 9/43 (20%) had negative Ab PET

  12. A4 Trial in Australia Over 1000 website registrations of interest Ab PET screening commenced early 2015 50 screening PET to date Aiming for 100 on study

  13. AIBL-VETSTau and Beta-Amyloid Deposition, Micro hemorrhage and Brain Function after Traumatic Brain Injury in War Veterans Award W81XWH-13-MRPRA-CSRA Principal Investigator: Christopher Rowe MD

  14. Future Directions for AIBL • Further refine prognostic value and comparative effectiveness of imaging and blood biomarkers • Examine genetic and environmental influences on rate of decline in Ab+ve HC • Serial tau imaging • Create new pools of Ab +ve for early intervention trials • Use AIBL infrastructure to support more A4 and DIAN therapy type trials

  15. Acknowledgements AIBL study participants and their families AIBL Study team David Ames Mary Barnes Kevin Barnham Shayne Bellingham Sabine Bird Julia Bomke PierrickBourgeat SveltanaBozinovski (nee Pejoska) Belinda Brown Rachel Buckley Samantha Burnham Ashley Bush PratishthaChatterjee Lesley Cheng Steven Collins Ian Cooke Kay Cox Elizabeth Cyarto David Darby James Doecke Vincent Dore Denise El-Sheikh Maree Farrow Noel Faux Michael Fenech Shane Fernandez Binosha Fernando Christopher Fowler Maxime Francois JurgenFripp Shaun Frost Sam Gardener Simon Gibson Veer Gupta David Hanson Karra Harrington Andy Hill Eugene Hone Maryam Hor Malcolm Horne Gareth Jones Adrian Kamer Yogi Kanagasingam Neil Killeen Hannah Korrel Fiona Lamb Nicola Lautenschlager Simon Laws Wayne Leifert Kate Lennon Hugo Leroux Qiao-Xin Li Yen Ying Lim Florence Lim Lucy Lim Linda Lockett Andrea Louey Kathy Lucas Lance Macaulay Lucy Mackintosh Ralph Martins Georgia Martins Paul Maruff Colin Masters Simon McBride AlissandraMcilroy Julie Nigro Steve Pedrini Kayla Perez Kelly Pertile Tenielle Porter Stephanie Rainey-Smith Carolina Restrepo Malcolm Riley Barbara Rita Cardoso Blaine Roberts Jo Robertson Mark Rodrigues Christopher Rowe Rebecca Rumble Tim Ryan Jack Sach Olivier Salvado Neil Saunders Greg Savage KaiKaiShen Brendan Silbert HarmidSohrabi Kevin Taddei Tania Taddei Sherilyn Tan Christine Thai Philip Thomas Brett Trounson Giuseppe Verdile Victor Villemagne Irene Volitakis Michael Vovos Larry Ward Andrew Watt Mike Weinborn Rob Williams Bill Wilson Michael Woodward Paul Yates Fernanda YevenesUgarte Ping Zhang AIBL is a large collaborative study and a complete list of contributors can be found at www.aibl.csiro.au

More Related